No. 1 Draft Pick: Tremendous Upside or Total Bust?
We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag:
The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your biotech, what would be your #1 pick. Go Cavs!
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass answer Keith's question. After Michael selected an immuno-oncology headline maker, David responds by drafting a boom-or-bust product with possibly the highest ceiling imaginable, Biogen's Alzheimer's drug BIIB037.
However, for all its potentia,l BIIB037 is surrounded by red flags. Watch and find out what they are and why David likes the drug enough to draft it No. 1 overall.
Will this stock be your next multi-bagger?
Give us five minutes, and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article No. 1 Draft Pick: Tremendous Upside or Total Bust? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.